newsfilter
← Latest News
GlobeNewswire·

Cassava Reports Q1 2025 Financials Results, Provides Business Update

License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08,